EnWave Corporation: Vaccine, Drug Process Patents Filed

2/22/2007


VANCOUVER, BRITISH COLUMBIA, Feb 22, 2007 (CCNMatthews via COMTEX News Network) --

EnWave Corporation (TSX VENTURE:ENW) (the "Company") wishes to report that Dr. Tim Durance, in conjunction with other researchers at the University of British Columbia (UBC), has filed US CIP and international PCT patent applications to protect radiant energy-vacuum methods for dehydrating biological materials (bioREV), including vaccines, drugs, enzymes, and living micro-organisms. This patent application, which the Company expects to be evaluated by PCT and US patent examiners within the next eighteen months, represents further intellectual property development of the technology initially invented for manufacture of biomaterial foams, first announced in a press release dated August 4, 2004. EnWave has received exclusive worldwide license to both technologies from UBC, granted by a recent amendment to the license agreement announced by the Company in a press release on December 3, 2004.

EnWave has also instructed UBC to proceed with the National Phase of patent filings for the biomaterials patent previously reported on August 4, 2004 and December 20, 2005. This will provide EnWave with patent protection in Canada, the United States, the European Union, Australia, India and China. The Company believes that these jurisdictions include almost all of the potential manufacturing sites, as well as the largest consumer markets, for potential tissue engineering and drug delivery products that could be produced using EnWave's bioREV technology.

About EnWave

EnWave is a spin-off company from the University of British Columbia focused on developing a new method for dehydrating biological materials using Radiant Energy Vacuum technology under the brand name bioREV. The bioREV technology combines microwave energy transfer with pressure control to alter structures, dehydrate and drive chemical reactions, creating unique product characteristics for various medical applications including dry vaccines, bone and tissue engineering and drug delivery.

ON BEHALF OF THE BOARD

Dr. Tim Durance, Chairman & CO-CEO

Safe Harbour for Forward-Looking Information Statements: This release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Forward-looking statements in this press release include: "should be able to help" and "foreseeable future". These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's REV technology can or will be used to develop materials for the tissue engineering or drug delivery markets; even if the Company's REV technology can be used as described in this news release, there is no guarantee that such use will result in orders for the Company's REV technology; changes in technology may render the Company's equipment offerings obsolete; changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business or intends to do business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

SOURCE: EnWave Corporation

EnWave Corporation Dr. Tim Durance Chairman and CO-CEO (604) 806-6110 EnWave Corporation Mr. John McNicol President & CO-CEO (604) 806-6110 (604) 806-6112 (FAX) Website: www.enwave.net
Copyright (C) 2007 CCNMatthews. All rights reserved.